Modern stock deposits arguing that increased Covid vaccines may not be necessary

Text size

Modern

shares, as well as shares of Covid vaccine manufacturers

BioNTech

i

Novavax,

they were slipping after a Lancet article suggested that a booster shot would not be necessary for most people.

In morning trading, shares of Moderna (MRNA) fell 5.8%, while BioNTech (BNTX) fell 5.6% and Novavax (NVAX) fell 2.4%.

Pfizer

(PFE), BioNTech’s partner, had fallen 2%. He

S&P 500

increased by 0.1%.

The Lancet article was a review of data from clinical trials as well as real-world efficacy. The authors, who included Marion Gruber and Philip Krause of the FDA, argue that there is no evidence that vaccines lose their ability to protect against “serious disease, even when there appear to be decreases over time in the ‘effectiveness of the vaccine against symptomatic diseases’.

The debate over whether to use booster shots in the U.S. is ongoing, even as Israel begins to discuss the possibility of a fourth shot. Continued vaccinations would produce long-term revenue streams for vaccine manufacturers.

Write to Ben Levisohn at [email protected]